[go: up one dir, main page]

MX2022007369A - Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t. - Google Patents

Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.

Info

Publication number
MX2022007369A
MX2022007369A MX2022007369A MX2022007369A MX2022007369A MX 2022007369 A MX2022007369 A MX 2022007369A MX 2022007369 A MX2022007369 A MX 2022007369A MX 2022007369 A MX2022007369 A MX 2022007369A MX 2022007369 A MX2022007369 A MX 2022007369A
Authority
MX
Mexico
Prior art keywords
quinolinonyl
compounds useful
compounds
substituted piperazine
cell activators
Prior art date
Application number
MX2022007369A
Other languages
English (en)
Inventor
Louis S Chupak
Robert G Gentles
Jayakumar Sankara Warrier
Xiaofan Zheng
Min Ding
Richard E Olson
Upender Velaparthi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022007369A publication Critical patent/MX2022007369A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de la fórmula (I) o una de sus sales, en donde: R1, R2, R3, R4, R5, R6 y m son como se definen en la presente. También se describen métodos para usar tales compuestos para inhibir la actividad de una o ambas de la diacilglicerol cinasa alfa (DGKa) y diacilglicerol cinasa zeta (DGK?), y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles en el tratamiento de infecciones víricas y trastornos proliferativos, tales como el cáncer.
MX2022007369A 2019-12-23 2020-12-22 Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t. MX2022007369A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201911053557 2019-12-23
PCT/US2020/066503 WO2021133748A1 (en) 2019-12-23 2020-12-22 Substituted quinolinonyl piperazine compounds useful as t cell activators

Publications (1)

Publication Number Publication Date
MX2022007369A true MX2022007369A (es) 2022-07-12

Family

ID=74195153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007369A MX2022007369A (es) 2019-12-23 2020-12-22 Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.

Country Status (12)

Country Link
US (1) US20230061608A1 (es)
EP (1) EP4081513B1 (es)
JP (1) JP7653441B2 (es)
KR (1) KR20220119456A (es)
CN (1) CN115103841B (es)
AU (1) AU2020414688A1 (es)
BR (1) BR112022012220A2 (es)
CA (1) CA3162992A1 (es)
ES (1) ES2998500T3 (es)
IL (1) IL294269A (es)
MX (1) MX2022007369A (es)
WO (1) WO2021133748A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022009631A2 (pt) * 2019-12-19 2022-08-09 Bristol Myers Squibb Co Combinações de inibidores de dgk e antagonistas do ponto de checagem
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686086B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2023122772A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122777A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
EP4472963A1 (en) * 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
JP2025508971A (ja) 2022-03-01 2025-04-10 インシリコ メディスン アイピー リミティド ジアシルグリセロールキナーゼ（ＤＧＫ）α阻害剤及びその使用
CN115124464B (zh) * 2022-07-04 2023-06-06 新乡学院 一种喹啉二酮磺酰哌嗪杂合体及其制备方法和应用
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
WO2025030002A2 (en) * 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025030163A1 (en) * 2023-08-02 2025-02-06 Horizon Therapeutics Ireland Dac Heterocyclic inhibitors of igf-1r for treatment of disease

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284768A (en) * 1980-07-02 1981-08-18 American Home Products Corporation 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
AU2006244068B9 (en) 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
WO2007114239A1 (ja) * 2006-03-30 2007-10-11 Sapporo Medical University DGKα阻害剤を含有する抗癌剤
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
PL2949670T3 (pl) 2009-12-10 2019-07-31 F. Hoffmann-La Roche Ag Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
US9221910B2 (en) 2010-03-05 2015-12-29 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
AU2011248083B2 (en) 2010-05-04 2015-09-10 Five Prime Therapeutics, Inc. Antibodies that bind CSF1R
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
NO2694640T3 (es) 2011-04-15 2018-03-17
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
CA2853889A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
BR112014018961A8 (pt) 2012-02-06 2017-07-11 Genentech Inc Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
HK1208233A1 (en) 2012-05-11 2016-02-26 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2890398A4 (en) 2012-08-31 2016-03-09 Five Prime Therapeutics Inc METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R)
BR112015022417A2 (pt) * 2013-03-14 2017-07-18 Convergene Llc métodos e composições para inibição de proteínas contendo bromodomínio
WO2020006018A1 (en) * 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators

Also Published As

Publication number Publication date
BR112022012220A2 (pt) 2022-09-13
CN115103841A (zh) 2022-09-23
JP2023508055A (ja) 2023-02-28
CA3162992A1 (en) 2021-07-01
EP4081513B1 (en) 2024-11-20
JP7653441B2 (ja) 2025-03-28
AU2020414688A1 (en) 2022-08-18
US20230061608A1 (en) 2023-03-02
CN115103841B (zh) 2024-12-27
KR20220119456A (ko) 2022-08-29
WO2021133748A1 (en) 2021-07-01
IL294269A (en) 2022-08-01
EP4081513A1 (en) 2022-11-02
ES2998500T3 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
MX2022007369A (es) Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
CL2020003260A1 (es) Compuestos de naftiridinona sustituidos útiles como activadores de células t
CL2022000485A1 (es) Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
MX2022006958A (es) Compuestos de quinazolinilo sustituidos utiles como activadores de celulas t.
CO2022008675A2 (es) Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t
BR112022012204A2 (pt) Compostos de heteroarila substituída úteis como ativadores de célula t
EA202190137A1 (ru) Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
BR112022012222A2 (pt) Derivados de piperazina substituídos úteis como ativadores de células t
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CO2018002061A2 (es) Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa
MX375625B (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
MX386726B (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
PE20180117A1 (es) Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer
EA201890052A1 (ru) Регуляторы nrf2
MX2023011715A (es) Compuestos de oxoisoindolina sustituidos con piridinilo.
CU20150053A7 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
BR112021024948A2 (pt) Moduladores de próxima geração de estimulador de genes de interferon (sting)
ECSP17069696A (es) Compuestos novedosos
PE20180355A1 (es) Desacetoxitubulisina h y analogos de esta
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
BR112017016883A2 (pt) compostos com atividade antitumoral